Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-10-05. The firm is engaged in advancing treatments for neurodegenerative diseases. The firm is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
Follow-Up Questions
Who is the CEO of Neurizon Therapeutics Ltd?
Dr. Michael Thurn is the Chief Executive Officer of Neurizon Therapeutics Ltd, joining the firm since 2023.
What is the price performance of NUZTF stock?
The current price of NUZTF is $0.0686, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Neurizon Therapeutics Ltd?
Neurizon Therapeutics Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Neurizon Therapeutics Ltd market cap?
Neurizon Therapeutics Ltd's current market cap is $36.6M
Is Neurizon Therapeutics Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Neurizon Therapeutics Ltd, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
